Eli Lilly and Co's migraine treatment Emgality on Tuesday became the first ...
NEW YORK - Eli Lilly and Co's migraine treatment Emgality on Tuesday became the first drug to gain U.S. approval for decreasing the frequency of episodic cluster headache attacks, the Food and Drug Administration saidFILE PHOTO: The logo of Lilly on a wall of Lilly France, part of Eli Lilly and Co, in Fegersheim near Strasbourg, France, February 1, 2018. REUTERS/Vincent Kessler
Cluster headaches are recurring, intense headaches that can occur several times daily during a “cluster period.” Lilly estimates that around 250,000 people suffer from the condition in the United States. The great majority of cluster headache cases are episodic, with attacks occurring in periods that can last from seven days to one year, followed by pain-free remission periods of at least one month.
Unlike migraines, which tend to be more prevalent in women, the condition is slightly more common in men.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Lilly's migraine drug as first ever cluster headache treatmentThe drug will be priced the same as for migraine on a per milligram basis, but the cost will vary depending on the length of treatment. Emgality for migraines costs $6,900 a year.
Read more »
Merck wins U.S. FDA approval for expanded use of antibioticThe U.S. Food and Drug Administration said https://www.fda.gov/news-events/press...
Read more »
FDA: Forever chemicals in food samples unlikely health riskWASHINGTON (AP) — The Food and Drug Administration found substantial levels of a worrisome class of nonstick, stain-resistant industrial compounds in some grocery store meats and seafood and in off-the-shelf chocolate cake, according to FDA researchers.
Read more »
FDA confirms PFAS chemicals are in the US food supplyPFAS, sometimes called 'forever chemicals,' have been linked to adverse health effects including liver damage, thyroid disease, decreased fertility, and cancer. Now they've been found in the US food supply, the FDA says
Read more »
Dietary supplement ingredient could cause a miscarriage or harm a fetus, FDA warns womenAn ingredient found in dietary supplements may cause a miscarriage or harm fetal development, the FDA warned women of childbearing age on Monday. Vinpocetine is a synthetically produced compound sold by itself or combined with other ingredients.
Read more »
FDA: Forever chemicals in food samples unlikely health riskThe Food and Drug Administration's first broad testing of food for a worrisome class of industrial compounds found high levels in some grocery store meats and seafood and in off-the-shelf chocolate cake.
Read more »
Cannabis stocks fall after FDA hearing on CBD finds conflicting views of substanceCannabis stocks were mostly lower Monday, as investors digested the first reports from Friday’s regulatory hearing on cannabis and its ingredients and the...
Read more »
Durbin alarmed that new FDA chief may 'disappoint' on e-cigsDick Durbin charged in an unusually sharp attack today that the acting FDA commissioner seemed to have 'no intention' of addressing youth e-cigarette use, which his predecessor deemed a public health epidemic
Read more »
FDA wins case against Florida stem cell clinic that blinded three womenThe FDA has won a federal judge's backing for its efforts to crack down on the rapidly growing stem cell industry that promises all kinds of unproven treatments for serious diseases.
Read more »
FDA wins major victory in campaign against stem cell clinicThe US Food and Drug Administration won a major legal victory in its ongoing effort to crack down on clinics marketing bogus and potentially hazardous stem cell products.
Read more »
Backing the FDA, a federal judge delivers a blow against bogus stem cell clinicsA federal judge has backed the FDA in its campaign to rein in stem cell clinics offering unproven and potentially hazardous “stem cell” treatments of a long list of diseases. Columnist hiltzikm explains:
Read more »